Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024
Aligos Therapeutics, Inc. - Common stock (ALGS)
Company Research
Source: GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will host a virtual Key Opinion Leader (KOL) event featuring Stephen Harrison, MD, Visiting Professor in the Radcliffe Department of Medicine at the University of Oxford, UK, to discuss the unmet need and current treatment landscape for patients with metabolic dysfunction-associated steatohepatitis (MASH, previously known as NASH) and Aligos’ Phase 2a HERALD study, intended to evaluate the safety and efficacy of ALG-055009, on Thursday, March 7, 2024 at 4:00 PM ET. To register, click here. During the event, Dr. Harrison will also discuss some of the key differentiating features of ALG-055009, a next generation thyroid hormone beta agonist. A live question and answer will follow the formal presentation.
Show less
Read more
Impact Snapshot
Event Time:
ALGS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALGS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALGS alerts
High impacting Aligos Therapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
ALGS
News
- Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024GlobeNewswire
- Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study [Yahoo! Finance]Yahoo! Finance
- Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 StudyGlobeNewswire
- Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD [Yahoo! Finance]Yahoo! Finance
- Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MDGlobeNewswire
ALGS
Earnings
- 3/12/24 - Beat
ALGS
Sec Filings
- 4/29/24 - Form ARS
- 4/29/24 - Form DEFA14A
- 4/29/24 - Form DEF
- ALGS's page on the SEC website